Osaterone acetate (also known as azasteroid or SH-265) is a synthetic steroid with antiandrogenic activity. Its synthesis involves the modification of testosterone, which is a naturally occurring male hormone. Research into osaterone acetate is focused on its potential as a treatment for various conditions, including acne, hirsutism (excessive hair growth), and prostate cancer. It works by blocking the action of testosterone in the body. Osaterone acetate has been studied in clinical trials for the treatment of acne and hirsutism. However, due to its side effects, its use is not widespread. Further research is needed to evaluate its efficacy and safety profile.'
osaterone acetate: structure given in first source; synthetic steroidal anti-androgen
ID Source | ID |
---|---|
PubMed CID | 114992 |
CHEBI ID | 81713 |
SCHEMBL ID | 528987 |
MeSH ID | M0383181 |
Synonym |
---|
osaterone acetate |
hipros |
tzp-4238 |
ccris 6738 |
17-alpha-acetoxy-6-chloro-2-oxa-4,6-pregnadiene-3,20-dione |
tzp 4238 |
cyclopenta(5,6)naphtho(1,2-c)pyran-2(4h)-one, 7-acetyl-7-(acetyloxy)-11-chloro-4a,4b,5,6,6a,7,8,9,9a,9b-decahydro-4a,6a-dimethyl-, (4ar,4bs,6as,7r,9as,9br)- |
17-(acetyloxy)-6-chloro-2-oxapregna-4,6-diene-3,20-dione |
7-acetyl-7-(acetyloxy)-11-chloro-4ar,4b,5,6,6as,7r,8,9,9as,9br-decahydro-4a,6a-dimethylcyclopenta(5,6)naphtho(1,2-c)pyran-2(4h)-one |
2-oxapregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-chloro- |
osaterone acetate ester |
[(1r,3as,3br,9ar,9bs,11as)-1-acetyl-5-chloro-9a,11a-dimethyl-7-oxo-2,3,3a,3b,9,9b,10,11-octahydroindeno[4,5-h]isochromen-1-yl] acetate |
105149-00-6 |
C18375 |
fr26fsv5ez , |
unii-fr26fsv5ez |
osaterone acetate [ema epar veterinary] |
osaterone acetate [jan] |
ypozane |
osaterone acetate ester [mi] |
2-oxochlormadinone acetate |
SCHEMBL528987 |
CHEBI:81713 |
17alpha-acetoxy-6-chloro-2-oxapregna-4,6-diene-3,20-dione |
KKTIOMQDFOYCEN-OFUYBIASSA-N |
osaterone acetate ester; tzp 4238 |
Q27155575 |
osaterone acetate (jan) |
D11105 |
DTXSID501030455 |
Osaterone acetate (OA) is an androgen receptor antagonist marketed for treatment of canine BPH.
Excerpt | Reference | Relevance |
---|---|---|
"Osaterone acetate (OA) is an androgen receptor antagonist marketed for treatment of canine BPH." | ( Prostatic fluid composition and semen quality in dogs with benign prostatic hyperplasia undergoing treatment with osaterone acetate. Bedin, S; Contiero, B; Ferré-Dolcet, L; Frigotto, L; Romagnoli, S, 2022) | 1.65 |
Excerpt | Reference | Relevance |
---|---|---|
" In intact dogs, OA exhibited a biexponential disposition with a very long half-life of 197." | ( Pharmacokinetics and biliary excretion of osaterone acetate, a new steroidal antiandrogen, in dogs. Honma, S; Iwamura, S; Koizumi, N; Minato, K; Tsukamoto, K, 2002) | 0.58 |
Class | Description |
---|---|
20-oxo steroid | An oxo steroid carrying an oxo group at position 20. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 23 (71.88) | 18.2507 |
2000's | 6 (18.75) | 29.6817 |
2010's | 2 (6.25) | 24.3611 |
2020's | 1 (3.13) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (37.71) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 5 (15.63%) | 5.53% |
Reviews | 1 (3.13%) | 6.00% |
Case Studies | 1 (3.13%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 25 (78.13%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |